In breast cancer cells, NAT10 knockdown reversed docetaxel‐induced EMT and restored sensitivity to docetaxel, as evidenced by upregulated CDH1 (E‐cadherin) expression and downregulated VIM (vimentin) expression.135. The gene discussed is NAT10; the disease is breast carcinoma.